Fig. 4

Validation of the MAPS and its prognostic value for ccRCC patients based on the E-MTAB-1980 cohort and GSE22541 cohort. A Distribution of the risk scores (the upper panel), distribution of prognostic status (the middle panel), and the expression of 12 genes in the MAPS in the E-MTAB-1980 cohort (the lower panel). The relative expression of each gene from the MAPS was normalized into Z-score. B) The time-dependent ROC curve of the MAPS for predicting the 1-,3- and 5-year OS of ccRCC patients based on the E-MTAB-1980 cohort. C The Kaplan–Meier survival of the MAPS in the E-MTAB-1980 cohort. D Distribution of the risk scores (the upper panel), distribution of prognostic status (the middle panel), and the expression of 12 genes from the MAPS in the GSE22541 cohort (the lower panel). The relative expression of each gene from the MAPS was normalized into Z-score. E The time-dependent ROC curve of the MAPS for predicting the 1-, 3- and 5-year DFS based on the GSE22541 cohort. F The Kaplan–Meier survival of the MAPS in the GSE22541 cohort. P was calculated using the log-rank test (C, F)